ABO2203's $7.2B Milestones Signal RNA Capacity Demand

Abogen Biosciences has entered a licensing and option agreement with Novartis that grants the an exclusive worldwide license to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager in development for autoimmune diseases.¹ The deal also gives Novartis exclusive options to license additional next-generation programs built on Abogen's proprietary RNA platform.

Abogen will receive an upfront payment of $575 million.¹ If all options on all programs are exercised, it could earn up to approximately $7.2 billion in development, regulatory, and commercial milestone payments, plus potential royalties on future sales. The transaction is subject to customary closing conditions, including regulatory clearances.

What Makes an mRNA-Encoded T-Cell Engager Different?

Conventional T-cell engagers are recombinant bispecific proteins, expressed in cell culture and purified before administration.¹ ABO2203 takes a different route. It uses mRNA to direct the patient's own cells to produce the CD19xCD3 molecule in vivo, with the goal of depleting and resetting B cells. Abogen describes this as a highly differentiated mechanism that could offer advantages over recombinant formats.

"This agreement marks an important milestone for Abogen, underscoring the broad potential of our RNA platform to expand beyond prophylactic vaccines," said Bo Ying, CEO, Abogen, in a press release.¹ "ABO2203 is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases, reflecting our commitment to delivering differentiated, accessible and scalable therapies for patients with B-cell-mediated disorders. We are thrilled to be able to accelerate ABO2203 and unlock new therapeutic targets through this agreement with Novartis."

Bispecific antibodies have drawn sustained investment because they avoid the cell collection and engineering steps that chimeric antigen receptor T-cell therapies require.¹ In vivo approaches push that logic further as these off-the-shelf products are unburdened by the complex logistics for cryopreservation of a cellular drug product

"Achieving effective and durable immune reset remains an important goal across a number of autoimmune diseases," said Fiona Marshall, President of Biomedical Research, Novartis, in the press release.¹ "mRNA-encoded T-cell engagers represent an innovative approach that could complement existing therapeutic modalities by enabling in vivo production of these molecules. We look forward to further developing the potential of ABO2203 and additional possible applications of Abogen's RNA platform."

What Do the Data Reveal About Manufacturing ABO2203?

The mRNA is synthesized from a linearized DNA template, enzymatically capped to a Cap1 structure, and purified twice on oligo(dT) resin.² The lipids are dissolved in ethanol and combined with the aqueous mRNA at a 1:3 volume ratio in a microfluidic apparatus. The formulation then undergoes dialysis and 0.2 µm sterile filtration. The resulting particles measure under 100 nm, a size the authors associate with lymphatic drainage after subcutaneous injection.

The researchers credit control over exposure to the encoded protein partly to tight consistency in manufacturing.² They also cite gradual absorption and rapid mRNA degradation.

Three patients with refractory immune thrombocytopenia secondary to lupus, Sjögren's syndrome, or antiphospholipid syndrome received an initial 120 µg dose followed by weekly 480 µg doses.² All three achieved complete peripheral B-cell depletion and complete platelet responses that held through 6 months. Adverse events were limited to grades 1 and 2, with no cytokine release syndrome. The authors note that microgram-level dosing, compared with milligram doses for in vivo chimeric antigen receptor T-cell approaches, could lower cost of goods.

Why Does This Deal Matter for Development and Manufacturing Teams?

Moving the active modality from a purified protein to an mRNA drug substance in lipid nanoparticles changes the manufacturing and control picture.¹ Teams would contend with in vitro transcription, mRNA purification, lipid sourcing, encapsulation efficiency, and particle size in place of cell line development and protein downstream processing. Teams will likely encounter a variety of engineering challenges of commercial-scale mRNA facilities, such as flammable solvent handling and limited commercial-scale equipment options.

Abogen states that it has built end-to-end capabilities spanning mRNA design, formulation development, and large-scale manufacturing under good manufacturing practice conditions, supported by an AI and automation-driven mRNA and lipid nanoparticle platform.¹ ABO1108, is a lyophilized mRNA shingles vaccine in Phase III trials in China. That freeze-dried format is relevant to cold-chain constraints that have shadowed mRNA products since the pandemic.

The option structure gives Novartis access to the underlying platform as well as a single asset.¹ It also reflects a broader trend: process knowledge and capacity first built for vaccines are being applied to repeat-dose therapeutics in chronic disease. Those therapeutics carry different expectations for tolerability, dosing consistency, and long-term supply.

References

1. Abogen Biosciences. Abogen announces licensing and option agreement with Novartis to advance mRNA-encoded T-cell engager and other potential RNA programs. PR Newswire. Published October 2, 2026. Accessed October 2, 2026. https://www.prnewswire.com/news-releases/abogen-announces-licensing-and-option-agreement-with-novartis-to-advance-mrna-encoded-t-cell-engager-and-other-potential-rna-programs-302896950.html
2. Wang M, Liu T, Dai Q, et al. mRNA-encoding CD19-targeting T cell engager for refractory immune thrombocytopenia. Cell. Published online September 18, 2026. doi:10.1016/j.cell.2026.08.039